Business Context and Reporting Period
This Form 8-K is a current report filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on February 14, 2006. The filing addresses "Other Events" related to the company's clinical trial progress for its drug candidate, CoFactor.
Key Financial Metrics
This filing is a current report regarding operational milestones and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Operational Updates
- Phase IIb Trial Progress: Patient recruitment for the multi-national Phase IIb clinical trial of CoFactor for metastatic colorectal cancer has surpassed the halfway point.
- Phase III Study Update: The company announced plans to conduct a second Phase III clinical trial evaluating CoFactor in a third-line setting for advanced breast cancer.
- Regulatory Status: The proposed Phase III trial is pending clearance regarding the clinical design from the US Food and Drug Administration (FDA).
Guidance, Outlook, and Risks
Management commentary is limited to the status of clinical trials. The primary contingency identified is the requirement for FDA clearance of the clinical design before the proposed Phase III trial for advanced breast cancer can proceed. No specific financial guidance or risk factors beyond the regulatory dependency were detailed in this specific filing.
Key Facts for Investor Verification
- Verify the exact number of patients enrolled to confirm the "half-way point" claim in the Phase IIb colorectal cancer trial.
- Confirm the timeline for FDA review and potential clearance of the Phase III breast cancer trial design.
- Review the full text of the press release (Exhibit 99.1) for additional details on trial endpoints and enrollment criteria.
- Note the discrepancy between the requested company name (Savara Inc.) and the actual registrant (AdventRX Pharmaceuticals, Inc.).